Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBITDA: 2018-2024

Historic EBITDA for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$63.3 million.

  • Silence Therapeutics' EBITDA rose 12.51% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 9.93%. This contributed to the annual value of -$63.3 million for FY2024, which is 1.65% up from last year.
  • As of FY2024, Silence Therapeutics' EBITDA stood at -$63.3 million, which was up 1.65% from -$64.4 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' EBITDA peaked at -$46.0 million during FY2020, and registered a low of -$64.4 million during FY2023.
  • In the last 3 years, Silence Therapeutics' EBITDA had a median value of -$63.3 million in 2024 and averaged -$62.9 million.
  • In the last 5 years, Silence Therapeutics' EBITDA tumbled by 58.58% in 2020 and then climbed by 3.16% in 2022.
  • Over the past 5 years, Silence Therapeutics' EBITDA (Yearly) stood at -$46.0 million in 2020, then slumped by 36.93% to -$63.0 million in 2021, then grew by 3.16% to -$61.0 million in 2022, then declined by 5.48% to -$64.4 million in 2023, then climbed by 1.65% to -$63.3 million in 2024.